Natco Pharma, on Saturday, said it had obtained a favourable ruling from a U.S. Court that paved way for launch of generic Copaxone used for treating multiple sclerosis during May, 2014.
“The company is pleased to announce the US.. Court of Appeals for the Federal Circuit ruling, reversing a district court’s finding related to Teva’s U.S. Patent for Copaxone,” Natco Pharma said in a filing to the Bombay Stock Exchange.
This would mean that Natco could launch the generic Copaxone through its marketing partner Mylan Inc, during May, 2014, subject to Food and Drug Administration (FDA) approval, it added.
Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis, Natco Pharma said.
The product is estimated to have clocked revenues of about $3.45 billion during 2012 in the U.S. market, it added.
